Albert Brzeczko - Acura Pharmaceuticals Insider

ACUR -- USA Stock  

USD 0.13  0.0246  15.91%

  VP
Dr. Albert W. Brzeczko Ph.D. serves as an Vice President, Technical Affairs of Acura Pharmaceutical Technologies, Inc. since February 2009. From 1999 through 2009, Dr. Brzeczko was Vice President, Global Pharma New Product Development and Pharma Technologies for International Specialty Products, Inc., a contract services group specializing in the development of technologies for the bioenhancement of poorly soluble drugs. Prior to 1999, Dr. Brzeczko held various positions of increasing responsibility in pharmaceutical product development with UPM Pharmaceuticals, Banner Pharmacaps, Mylan Laboratories, and DuPont Merck
Age: 59  VP Since 2009  Ph.D    
847-705-7709  http://www.acurapharm.com
Brzeczko received a BS degree in biochemistry and a Ph.D. in pharmaceutical sciences from the University of Maryland.

Albert Brzeczko Latest Insider Activity

Management Efficiency

The company has return on total asset (ROA) of (75.63) % which means that it has lost $75.63 on every $100 spent on asset. This is way below average.
The company currently holds 2.23 M in liabilities with Debt to Equity (D/E) ratio of 226.1 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Acura Pharmaceuticals has Current Ratio of 0.24 indicating that it has a negative working capital and may not be able to pay financial obligations when they are due.

Similar Executives

Found 2 records

VP Since

Christopher LeamonEndocyte
2000
Scot HarperEndocyte
2013

Entity Summary

Acura Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the research, development, and commercialization of technologies and products to address medication abuse and misuse. The company was founded in 1935 and is based in Palatine, Illinois. Acura Pharmaceuticals operates under Drug Manufacturers - Specialty Generic classification in USA and traded on BATS Exchange. It employs 14 people.Acura Pharmaceuticals [ACUR] is traded as part of a regulated electronic over-the-counter service offered by the NASD. Acura Pharmaceuticals is listed under Pharmaceutical Products category by Fama And French industry classification.

Acura Pharmaceuticals Leadership Team

George Ross, Independent Director
Robert Jones, CEO and President and Director
Bruce Wesson, Independent Director
Peter Clemens, CFO, Principal Accounting Officer, Sr. VP and Secretary
Albert Brzeczko, VP of Technical Affairs
Immanuel Thangaraj, Independent Director
James Emigh, Vice President - Corporate Development
Robert Seiser, VP, Treasurer and Corporate Controller
Bradley Rivet, VP of Marketing
William Skelly, Independent Director

Stock Performance Indicators

Did you try this?

Run Premium Stories Now

   

Premium Stories

Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
All  Next Launch Premium Stories

Acura Pharmaceuticals Pair Correlation

Equities Pair Trading Analysis

Correlation analysis and pair trading evaluation for Acura Pharmaceuticals and China Cord Blood. Pair trading can be used as a hedging technique within a particular sector or industry or even over random equities to generate better risk-adjusted return
Run Pair Correlation  
Check also Trending Equities. Please also try Portfolio Manager module to state of the art portfolio manager to monitor and improve performance of your invested capital.
Search macroaxis.com